Related Experiment Video

Updated: Apr 28, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.3K

The ins and outs of angiotensin processing within the kidney

Bryan A Wilson1, Allyson C Marshall1, Ebaa M Alzayadneh1

  • 1Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina.

American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
|June 20, 2014
PubMed

Insights

The kidney has its own renin-angiotensin system (RAS) within tubular cells. This review explores how angiotensin peptides are formed and broken down in the kidney, focusing on opposing signaling pathways.

Area of Science:

  • Nephrology
  • Endocrinology
  • Molecular Biology

Background:

  • The kidney is a primary target of the renin-angiotensin system (RAS).
  • Renal cells, including tubular epithelium, possess an intrinsic RAS.
  • The renal RAS comprises opposing arms: ANG II-AT1 receptor and ANG-(1-7)-AT7/Mas receptor.

Purpose of the Study:

  • To review the extracellular and intracellular pathways governing angiotensin peptide formation and metabolism in renal proximal tubules.
  • To elucidate the functional significance of the intrinsic renal RAS.

Main Methods:

  • Literature review of existing research on renal RAS.
  • Analysis of pathways for angiotensin peptide synthesis and degradation.
  • Examination of intracellular and extracellular mechanisms within renal proximal tubules.

Main Results:

  • The kidney contains a functional intrinsic RAS.
  • Two opposing arms, ANG II-AT1R and ANG-(1-7)/Mas, regulate renal function.
  • Both extracellular and intracellular pathways are involved in angiotensin metabolism within the kidney.

Conclusions:

  • The intrinsic renal RAS plays a crucial role in kidney physiology.
  • Understanding these pathways is vital for targeting renal diseases.
  • Further research into renal angiotensin metabolism can reveal therapeutic strategies.
Keywords:
angiotensin IIangiotensin-(1–7)fetal programmingkidneymetabolismpeptidase

More Related Videos

Nitropeptide Profiling and Identification Illustrated by Angiotensin II07:31

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

5.1K
Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

10.6K

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
30.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Introduction to Urinary System01:13

Introduction to Urinary System

The urinary system consists of two kidneys, two ureters, the urinary bladder, and the urethra.
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...
11.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K